AIMA
ABBV icon

Ables Iannone Moore & Associates’s AbbVie ABBV Stock Holding History

Ables Iannone Moore & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-239
Closed -$37K – 75
2023
Q4 		$37K Buy
+239
New +$34.8K 0.03% 113

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Ables Iannone Moore & Associates's ABBV Position: Q1 2024 in Review

Ables Iannone Moore & Associates sold out of AbbVie (ABBV) in Q1 2024, closing a stake of 239 shares — an estimated $37K sold.

Ables Iannone Moore & Associates first reported a position in ABBV in Q4 2023 and held it in 1 quarter. The position peaked at $37K in Q4 2023. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

  • Ables Iannone Moore & Associates reported no remaining AbbVie position as of Q1 2024 after selling out during the quarter.
  • Ables Iannone Moore & Associates sold 239 AbbVie shares in Q1 2024, an estimated $37K.
  • Ables Iannone Moore & Associates first reported a position in AbbVie in Q4 2023 and held it in 1 quarter.
  • Ables Iannone Moore & Associates's AbbVie position peaked at $37K in Q4 2023.
  • 3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on Ables Iannone Moore & Associates's 13F filing for Q1 2024, filed 30 Apr 2024.